-
PDF
- Split View
-
Views
-
Cite
Cite
Christoph Wanner, Mark E Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Egon Pfarr, Sven Schnaidt, Maximilian von Eynatten, Jyothis T George, Nicholas D Gollop, Nikolaus Marx, John H Alexander, Bernard Zinman, Vlado Perkovic, on behalf of the CARMELINA investigators, Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial, Clinical Kidney Journal, Volume 14, Issue 9, September 2021, Page 2136, https://doi.org/10.1093/ckj/sfab104
- Share Icon Share
Clinical Kidney Journal, sfaa225, https://doi.org/10.1093/ckj/sfaa225
In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’
Comments